Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596372 · ClinicalTrials.gov registry record · Phase 1
Study of BAY1834942 in Patients With Solid Tumors
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03596372 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 30 participants.
The verdict
NCT03596372, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6) antibody BAY1834942 in patients with advanced solid tumors known to have a prevalence for CEACAM6 expression. The study consists of dose escalation and a tumor type-specific expansion.
Interventions
- DRUG BAY1834942
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596372
The ClinicalTrials.gov registry entry for NCT03596372 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY1834942 is the first listed.
NCT03596372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596372 about?
NCT03596372 is a clinical study titled "Study of BAY1834942 in Patients With Solid Tumors". This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6) antibody BAY1834942 in patien...
What is the current status of trial NCT03596372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-06-19. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT03596372?
The interventions under investigation include: BAY1834942 (DRUG).
Who is sponsoring clinical trial NCT03596372?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.